Applying the new STEMI guidelines: 1. Reperfusion in acute ST-segment elevation myocardial infarction

Bogaty, Peter; Buller, Christopher E.; Dorian, Paul; O'Neill, Blair J.; Armstrong, Paul W.
October 2004
CMAJ: Canadian Medical Association Journal;10/26/2004, Vol. 171 Issue 9, p1039
Academic Journal
Reports on the application of the guidelines of the American Heart Association on the selection of patients for reperfusion after acute St-segment elevation myocardial infarction (STEMI). Diagnosis for a female patient experiencing jaw discomfort accompanied by diaphoresis and nausea; Factors to be considered in performing reperfusion in STEMI; Reasons for the selection of immediate on-site fibrinolysis for patients with acute myocardial infarction.


Related Articles

  • STREAM and FAST-MI–Pharmacoinvasive therapy: A continued role for fibrinolysis in the primary PCI era. ElGuindy, Ahmed M. // Global Cardiology Science & Practice;2014, Vol. 2014 Issue 2, p1 

    Data from the Strategic Reperfusion Early After Myocardial Infarction (STREAM) trial6 and 5-year results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI)7 are evaluated for further evidence on the effectiveness and safety of a pharmacoinvasive...

  • Contemporary Therapy of Acute ST-Elevation Myocardial Infarction. Armstrong, Paul W. // Texas Heart Institute Journal;2009, Vol. 36 Issue 4, p273 

    The article focuses on contemporary therapy of acute ST-elevation myocardial infarction (STEMI). It is said that STEMI serves a key role in the development of more broadly applicable diagnostic and treatment methods. It adds that the choice of reperfusion therapy is optimized based on the...

  • Management of microvascular dysfunction and reperfusion injury. Prasad, A.; Gersh, B. J. // Heart;Dec2005, Vol. 91 Issue 12, p1530 

    The article presents a discussion on the management of microvascular dysfunction and reperfusion injury. Myocardial contrast echo-cardiography has been available for a many years for the assessment of myocardial perfusion, and the recent availability of intravenous contrast agents has made it...

  • A Review of Cardiogenic Shock in Acute Myocardial Infarction. Khalid, L.; Dhakam, S. H. // Current Cardiology Reviews;2008, Vol. 4 Issue 1, p34 

    Cardiogenic shock continues to be the most common cause of death in patients hospitalized with acute myocardial infarction. It has also been frequently associated with ST-segment elevation myocardial infarction (STEMI) and patients with co-morbidities. Cardiogenic shock presents with low...

  • Ex Vivo and In Vivo Approaches to Study Mechanisms of Cardioprotection Targeting Ischemia/Reperfusion (I/R) Injury: Useful Techniques for Cardiovascular Drug Discovery. Vidavalur, Ramesh; Swarnakar, Snehasikta; Thirunavukkarasu, Mahesh; Samuel, Samson Mathews; Maulik, Nilanjana // Current Drug Discovery Technologies;Dec2008, Vol. 5 Issue 4, p269 

    The last few decades have seen significant advancement in the therapy of Ischemic Heart Diseases (IHD). This is a direct outcome of the increasing knowledge of the molecular mechanisms involved during an ischemic insult of the myocardium. Even then there is still a major unmet need for better...

  • Wide variation in MI management in England + Wales.  // PharmacoEconomics & Outcomes News;7/1/2006, Issue 506, p5 

    This article discusses research being done on myocardial infarction (MI) management and outcomes in Great Britain. It references a study by J. Birkhead et al published in the June 3, 2006 issue of the "British Medical Journal." Information is presented on patients admitted in both interventional...

  • Invasive evaluation of patients after reperfused STEMI: One-stop-shop for anatomy and physiology. Samady, Habib // Journal of Nuclear Cardiology;Sep2010, Vol. 17 Issue 5, p775 

    The author reflects on the value of the use of fractional flow reserve (FFR) for assessing the severity of lesion in reperfused ST elevation myocardial infarction (STEMI) patients by interventional cardiologists. He describes the challenge of achieving myocardial reperfusion to stop the ongoing...

  • Cardiovascular disease: MYDGF promotes heart repair after myocardial infarction. Cully, Megan // Nature Reviews Drug Discovery;Mar2015, Vol. 14 Issue 3, p164 

    The article reports on the results of a study published in the "Nature Medicine" journal which showed the role of myeloid-derived growth factor (MYDGF) in promoting heart repair. The study used a mouse model that simulates reperfusion therapy after myocardial infarction (MI) to explore the...

  • Effect of Clopidogrel Pretreatment Before Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction Treated With Fibrinolytics: The PCI-CLARITY Study. Sabatine, Marc S.; Cannon, Christopher P.; Gibson, C. Michael; López-Sendón, Jose L.; Montalescot, Gilles; Theroux, Pierre; Lewis, Basil S.; Murphy, Sabina A.; McCabe, Carolyn H.; Braunwald, Eugene // JAMA: Journal of the American Medical Association;9/14/2005, Vol. 294 Issue 10, p1224 

    Context The benefit of clopidogrel pretreatment before percutaneous coronary intervention (PCI) remains debated and its use has not been universally adopted. Objective To determine if clopidogrel pretreatment before PCI in patients with recent ST-segment elevation myocardial infarction (STEMI)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics